Maternal exposure to methotrexate and birth defects: A population-based study

American Journal of Medical Genetics, Part A

Volumn 164, Issue 9, 2014, Pages 2212-2216

  Dawson, April L ^a   Riehle Colarusso, Tiffany ^a   Reefhuis, Jennita ^a   Arena, J Fernando ^a  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Birth defects; Congenital heart defects; Methotrexate

Indexed keywords

METHOTREXATE;

ADULT; ARTICLE; BIRTH DEFECT; CASE CONTROL STUDY; CLEFT PALATE; CLINICAL ARTICLE; CONCEPTION; CONGENITAL DIAPHRAGM HERNIA; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; CRANIOFACIAL SYNOSTOSIS; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; FALLOT TETRALOGY; FEMALE; GESTATIONAL AGE; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYPOSPADIAS; JUVENILE RHEUMATOID ARTHRITIS; MICROTIA; PRIORITY JOURNAL; PULMONARY VALVE STENOSIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; ADVERSE EFFECTS; CONGENITAL ABNORMALITIES; PREGNANCY; PRENATAL EXPOSURE; PREVENTION AND CONTROL;

CONGENITAL ABNORMALITIES; FEMALE; HUMANS; MATERNAL EXPOSURE; METHOTREXATE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 84905921557     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.36625     Document Type: Article

References (20)

1. Addar MH. 2004. Methotrexate embryopathy in a surviving intrauterine fetus after presumed diagnosis of ectopic pregnancy: Case report. J Obstet Gynaecol Can 26:1001-1003.
2. Chapa JB, Hibbard JU, Weber EM, Abramowicz JS, Verp MS. 2003. Prenatal diagnosis of methotrexate embryopathy. Obstet Gynecol 101:1104-1107.
3. Cogswell ME, Bitsko RH, Anderka M, Caton AR, Feldkamp ML, Hockett Sherlock SM, Meyer RE, Ramadhani T, Robbins JM, Shaw GM, Mathews TJ, Royle M, Reefhuis J, National Birth Defects Prevention Study. 2009. Control selection and participation in an ongoing, population-based, case-control study of birth defects: The National Birth Defects Prevention Study. Am J Epidemiol 170:975-985.
4. Dalrymple JM, Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Barclay ML. 2008. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 58:3299-3308.
5. Dupont WD, Plummer WD Jr. 1990. Power and sample size calculations. A review and computer program. Control Clin Trials 11:116-128.
6. Feldkamp M, Carey JC. 1993. Clinical teratology counseling and consultation case report: Low dose methotrexate exposure in the early weeks of pregnancy. Teratology 47:533-539.
7. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. 2000. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 343:1608-1614.
8. Hyoun SC, Obican SG, Scialli AR. 2012. Teratogen update: Methotrexate. Birth Defects Res A Clin Mol Teratol 94:187-207.
9. Korell J, Stamp LK, Barclay ML, Dalrymple JM, Drake J, Zhang M, Duffull SB. 2013. A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cells. Clin Pharmacokinet 52:475-485.
10. Kremer JM, Galivan J, Streckfuss A, Kamen B. 1986. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 29:832-835.
11. Lloyd ME, Carr M, Mcelhatton P, Hall GM, Hughes RA. 1999. The effects of methotrexate on pregnancy, fertility and lactation. QJM 92:551-563.
12. Milunsky A, Graef JW, Gaynor MFJr. 1968. Methotrexate-induced congenital malformations. J Pediatr 72:790-795.
13. Nguyen C, Duhl AJ, Escallon CS, Blakemore KJ. 2002. Multiple anomalies in a fetus exposed to low-dose methotrexate in the first trimester. Obstet Gynecol 99:599-602.
14. Piggott KD, Sorbello A, Riddle E, DeCampli W. 2011. Congenital cardiac defects: A possible association of aminopterin syndrome and in utero methotrexate exposure? Pediatr Cardiol 32:518-520.
15. Poggi SH, Ghidini A. 2011. Importance of timing of gestational exposure to methotrexate for its teratogenic effects when used in setting of misdiagnosis of ectopic pregnancy. Fertil Steril 96:669-671.
16. Rasmussen SA, Olney RS, Holmes LB, Lin AE, Keppler-Noreuil KM, Moore CA. 2003. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 67:193-201.
17. Richardson A. 2012. Medical management of ectopic pregnancy: A 10-year case series. Hum Fertil (Camb) 15:116-120.
18. Seidahmed MZ, Shaheed MM, Abdulbasit OB, Al Dohami H, Babiker M, Abdullah MA, Abomelha AM. 2006. A case of methotrexate embryopathy with holoprosencephaly, expanding the phenotype. Birth Defects Res A Clin Mol Teratol 76:138-142.
19. U.S. Food and Drug Administration. Methotrexate sodium label information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/011719s117lbl.pdf. Accessed July 31, 2013.
20. Yoon PW, Rasmussen SA, Lynberg MC, Moore CA, Anderka M, Carmichael SL, Costa P, Druschel C, Hobbs CA, Romitti PA, Langlois PH, Edmonds LD. 2001. The National Birth Defects Prevention Study. Public Health Rep 116:32-40.